Extended anticoagulation in provoked VTE with persistent risk factors: A meta-analysis of randomised trials
Romanian Journal of Cardiology · 01.06.2026
DOI: 10.2478/rjc-2026-0014 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Romanian Journal of Cardiology, online erschienen am 01.06.2026. Verfasst von Mohsin Raj Mantoo und 6 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients with venous thromboembolism (VTE) triggered by transient factors are typically treated with anticoagulants for 3–6 months. However, those with coexisting long-term non-malignant conditions may continue to carry a meaningful risk of recurrence beyond the initial treatment period. The benefit of extended anticoagulation in this subgroup remains uncertain.
Objectives
To evaluate the efficacy and safety of continued and reduced-dose direct oral anticoagulant (DOAC) therapy compared with no extended anticoagulation or aspirin in patients with provoked VTE and persistent non-malignant risk factors.
Methods
We performed a systematic review and meta-analysis of randomised controlled trials in accordance with PRISMA guidelines. MEDLINE, Embase and CENTRAL were searched from inception through 15 October 2025. Eligible trials enrolled adults with provoked VTE and persistent non-malignant risk factors who had completed initial anticoagulation and compared extended DOAC therapy with placebo, aspirin or discontinuation. Primary outcomes were recurrent VTE and major bleeding. Risk ratios (RRs) were pooled using random-effects models, with fixed-effects analyses as sensitivity.
Results
Three trials, including 2498 participants, were analysed. Continued DOAC therapy was associated with a lower incidence of recurrent VTE compared with placebo or aspirin (RR 0.25, 95% confidence interval [CI] 0.07–0.98; I 2 34%). Reduced-dose regimens demonstrated comparable effectiveness (RR 0.21, 95% CI 0.11–0.41). Major bleeding events were infrequent across all groups, and no clear excess risk was observed with extended therapy (RR 2.38, 95% CI 0.87–6.53; I 2 0%).
Conclusion
Among patients with provoked VTE and ongoing non-malignant risk factors, extended DOAC therapy appears to reduce recurrence without a definite increase in major bleeding. These findings support a more individualised approach to treatment duration in this intermediate-risk population.
Zitieren
APA
Mantoo, M. R., Mantoo, S. R., Majeed, M. W., Kulkarni, A., Lone, H. P., Mansoor, M., & Roy, A. (2026). Extended anticoagulation in provoked VTE with persistent risk factors: A meta-analysis of randomised trials. Romanian Journal of Cardiology. https://doi.org/10.2478/rjc-2026-0014
Vancouver
Mantoo MR, Mantoo SR, Majeed MW, Kulkarni A, Lone HP, Mansoor M, et al. Extended anticoagulation in provoked VTE with persistent risk factors: A meta-analysis of randomised trials. Romanian Journal of Cardiology. 2026. doi:10.2478/rjc-2026-0014
BibTeX
@article{Mantoo2026,
author = {Mantoo, Mohsin Raj and Mantoo, Saadat Raj and Majeed, Mir Wajid and Kulkarni, Anushka and Lone, Haziq Parveez and Mansoor, Mazin and Roy, Ambuj},
title = {Extended anticoagulation in provoked VTE with persistent risk factors: A meta-analysis of randomised trials},
journal = {Romanian Journal of Cardiology},
year = {2026},
doi = {10.2478/rjc-2026-0014}
}
EUVIMED